CASR and Alzheimer disease: Third, any possible AD-promoting effects of CaSR PAMs (calcimimetics) in humans should be thoroughly investigated since in our preclinical in vitro AD model PAM NPS R-568 significantly increased Aβ42/Aβ42-os release from untransformed human adult cortical astrocytes (Armato et al., 2013).